Odyssey Investment Partners to sell EAG to Eurofins

Eurofins Scientific has agreed to acquire EAG Laboratories from Odyssey Investment Partners. No financial terms were disclosed. The deal is expected to close in the next few months. Based in San Diego, EAG is a scientific services company that provides analytical testing and consulting solutions.

Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces that it has signed an agreement to acquire EAG Laboratories (“EAG”), a leading global scientific services company providing analytical testing and consulting solutions to a diverse and demanding set of end markets, from Odyssey Investment Partners. The transaction is expected to close in the next few months, subject to the fulfillment of customary closing conditions.

EAG is headquartered in San Diego and has 21 laboratories in 18 locations worldwide, serving approximately 4000 customers with revenue generated from more than 50 countries. It believes it is the largest independent US-centric platform in the testing, inspection and certification (TIC) market, and is a highly differentiated player in high-science analytical testing and consulting solutions. EAG serves three main markets, namely Material and Engineering Sciences, Agroscience and Biopharmaceuticals. The company has grown significantly over its 40-year history, both organically and through acquisitions.

Today EAG employs over 1000 highly educated and talented scientists and support personnel, and expects to generate revenues in excess of US$ 220m in 2017, with an EBITDA margin close to 30%. The agreed acquisition price is US$780m on a cash free debt free basis. As Eurofins and EAG have almost no geographic overlap, no site consolidations or restructuring costs are foreseen as a result of this acquisition. Synergetic top line market effects are expected in Agroscience and Biopharmaceuticals products testing based on cross selling to each organization’s clients in the other company’s geographic base. Based on EAG’s historic and projected profitability, the transaction should be immediately margin accretive for Eurofins after closing.

EAG is also a leading North American provider of advanced chemical testing services for pesticides, industrial and household chemicals, an area where Eurofins had little presence so far in the USA. It provides end-to-end support for e-fate, metabolism, eco-toxicology and residue studies required for pesticide and chemical regulatory testing to support global registration requirements. The company has extensive expertise to test molecules with highly complex profiles. EAG’s agroscience business is highly complementary to the existing Eurofins agroscience business in terms of capabilities/capacities and particularly geography.

In the biopharmaceutical testing market, EAG adds a highly desirable asset to the Eurofins BioPharma Product Testing group in a geographic area of the USA where Eurofins had no presence so far. EAG’s laboratory in Missouri provides an extensive range of small molecule and biologics testing and characterization services to a broad range of biopharmaceutical customers. The company provides advanced testing and scientific support services from a well-equipped and state-of-the-art facility. EAG supports biopharmaceutical, generic and biosimilar customers from the research and development phase through to commercialization.

Dr. Gilles Martin, Eurofins CEO

For more information, please visit www.eurofins.com


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    EAG Laboratories. (2017, September 19). Odyssey Investment Partners to sell EAG to Eurofins. AZoM. Retrieved on July 04, 2020 from https://www.azom.com/news.aspx?newsID=48179.

  • MLA

    EAG Laboratories. "Odyssey Investment Partners to sell EAG to Eurofins". AZoM. 04 July 2020. <https://www.azom.com/news.aspx?newsID=48179>.

  • Chicago

    EAG Laboratories. "Odyssey Investment Partners to sell EAG to Eurofins". AZoM. https://www.azom.com/news.aspx?newsID=48179. (accessed July 04, 2020).

  • Harvard

    EAG Laboratories. 2017. Odyssey Investment Partners to sell EAG to Eurofins. AZoM, viewed 04 July 2020, https://www.azom.com/news.aspx?newsID=48179.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback